Hui Feng

Hui Feng

Departments of Pharmacology and Medicine, Boston University School of Medicine

Affiliated withBoston University School of MedicineXinyu University

Research Area

Biography

Trained as a physician and cancer biologist, Dr. Feng has applied the zebrafish as a model to study MYC-driven cancers over seventeen years. Her laboratory at Boston University (www.bu.edu/zgct) utilizes multiple zebrafish models of cancer to gain mechanistic insights into MYC-mediated oncogenic pathways and identify novel therapeutic targets for MYC-driven cancers.

JoVE Journal Publications

ArticleTotal : 2
Year
In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish
Publication title

Cited by 5

2020
2025

Other Publications

Article
Year
BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.

Leukemia| PubMed ID: 24342948

2014
2014
2015
2015
2016
Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights.

Advances in experimental medicine and biology| PubMed ID: 27165361

2016
2017
2017
2017
2018
Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor.

International journal of molecular sciences| PubMed ID: 29735912

2018
2018
2018
2018
2019
2019
2019
2019
Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan.

Molecular cancer research : MCR| PubMed ID: 31932471

2020
2020
2020
2024